1. Home
  2. SMCI vs INSM Comparison

SMCI vs INSM Comparison

Compare SMCI & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SMCI
  • INSM
  • Stock Information
  • Founded
  • SMCI 1993
  • INSM 1988
  • Country
  • SMCI United States
  • INSM United States
  • Employees
  • SMCI N/A
  • INSM N/A
  • Industry
  • SMCI Computer Manufacturing
  • INSM Biotechnology: Pharmaceutical Preparations
  • Sector
  • SMCI Technology
  • INSM Health Care
  • Exchange
  • SMCI Nasdaq
  • INSM Nasdaq
  • Market Cap
  • SMCI 26.1B
  • INSM 29.0B
  • IPO Year
  • SMCI 2007
  • INSM 2000
  • Fundamental
  • Price
  • SMCI $55.35
  • INSM $161.17
  • Analyst Decision
  • SMCI Buy
  • INSM Strong Buy
  • Analyst Count
  • SMCI 17
  • INSM 19
  • Target Price
  • SMCI $47.47
  • INSM $152.71
  • AVG Volume (30 Days)
  • SMCI 30.5M
  • INSM 2.2M
  • Earning Date
  • SMCI 11-04-2025
  • INSM 10-30-2025
  • Dividend Yield
  • SMCI N/A
  • INSM N/A
  • EPS Growth
  • SMCI N/A
  • INSM N/A
  • EPS
  • SMCI 1.68
  • INSM N/A
  • Revenue
  • SMCI $21,972,042,000.00
  • INSM $398,105,000.00
  • Revenue This Year
  • SMCI $49.57
  • INSM $32.44
  • Revenue Next Year
  • SMCI $24.52
  • INSM $123.99
  • P/E Ratio
  • SMCI $32.82
  • INSM N/A
  • Revenue Growth
  • SMCI 46.59
  • INSM 21.15
  • 52 Week Low
  • SMCI $17.25
  • INSM $60.40
  • 52 Week High
  • SMCI $66.44
  • INSM $162.44
  • Technical
  • Relative Strength Index (RSI)
  • SMCI 73.76
  • INSM 79.92
  • Support Level
  • SMCI $50.80
  • INSM $136.62
  • Resistance Level
  • SMCI $48.15
  • INSM $148.22
  • Average True Range (ATR)
  • SMCI 2.41
  • INSM 4.38
  • MACD
  • SMCI 1.15
  • INSM 0.56
  • Stochastic Oscillator
  • SMCI 82.68
  • INSM 98.49

About SMCI Super Micro Computer Inc.

Super Micro Computer Inc provides high-performance server technology services to cloud computing, data centers, high-performance computing, and the Internet of Things embedded markets. Its solutions include servers, storage systems, modular blade servers, workstations, full-rack scale solutions, networking devices, server sub-systems, and server management. These turn-key solutions are designed, developed, validated, and installed for AI datacenters. The company has one operating segment that develops and provides high-performance server solutions based upon a, modular and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: